Implementation of quantitative and systems pharmacology in large pharma

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 10, 2014, Pages

  Visser, S A G ^a   De Alwis, D P ^a   Kerbusch, T ^b   Stone, J A ^a   Allerheiligen, S R B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; ETANERCEPT; INFLIXIMAB; ODANACATIB; TILDRAKIZUMAB; USTEKINUMAB;

BIOEQUIVALENCE; CLINICAL DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; INVESTMENT; NONHUMAN; PHARMACOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIMULATION;

EID: 84926498217     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.40     Document Type: Review

References (50)

1. Krishna, R., Schaefer, H.G. & Bjerrum, O.J. Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development. J. Clin. Pharmacol. 47, 738-743 (2007).
2. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
3. Allerheiligen, S.R. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin. Pharmacol. Ther. 88, 135-137 (2010).
4. Morgan, P. et al. Can the fow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419-424 (2012).
5. Milligan, P.A. et al. Model-based drug development: a rational approach to effciently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
6. Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569 (2013).
7. Zineh, I. & Woodcock, J. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin. Pharmacol. Ther. 93, 515-525 (2013).
8. Sorger, P.K. et al. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. An NIH White Paper, QSP Workshop Group (2011). http://isp.hms.harvard.edu/wordpress/wp-content/uploads/2011/10/NIH-Systems-Pharma-Whitepaper-Sorger-et-al-2011.pdf
9. van der Graaf, P.H. & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011).
10. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E. & Gallo, J.M. Merging systems biology with pharmacodynamics. Sci Transl Med. 21, 126ps7 (2013).
11. Vicini, P. & van der Graaf, P.H. Systems pharmacology for drug discovery and development: paradigm shift or fash in the pan? Clin. Pharmacol. Ther. 93, 379-381 (2013).
12. Visser, S.A. et al. Model-based drug discovery: implementation and impact. Drug Discov. Today 18, 764-775 (2013).
13. Simonds, N.I. et al. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J. Natl. Cancer Inst. 105, 929-936 (2013).
14. Rogers, M., Lyster, P. & Okita, R. NIH Support for the Emergence of Quantitative and Systems Pharmacology. CPT Pharmacometrics Syst. Pharmacol. 2, e37 (2013).
15. van der Graaf, P.H. CPT: Pharmacometrics and Systems Pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, e8 (2012).
16. Zhao, S. & Iyengar, R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 52, 505-521 (2012).
17. Jenkins, S.L. & Ma'ayan, A. Systems pharmacology meets predictive, preventive, personalized and participatory medicine. Pharmacogenomics 14, 119-122 (2013).
18. Bai, J.P. & Abernethy, D.R. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu. Rev. Pharmacol. Toxicol. 53, 451-473 (2013).
19. Rodriguez, B., Burrage, K., Gavaghan, D., Grau, V., Kohl, P. & Noble, D. The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin. Pharmacol. Ther. 88, 130-134 (2010).
20. Berger, S.I., Ma'ayan, A. & Iyengar, R. Systems pharmacology of arrhythmias. Sci. Signal. 3, ra30 (2010).
21. Berger, S.I. & Iyengar, R. Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 129-135 (2011).
22. Winter, G.E. et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat. Chem. Biol. 8, 905-912 (2012).
23. Orrell, D. et al. Predicting the effect of drug combination schedules on xenograft growth using the virtual tumor. Cancer Res. 71, 8S1 (2011).
24. Ajmera, I., Swat, M., Laibe, C., Novère, N.L. & Chelliah, V. The impact of mathematical modeling on the understanding of diabetes and related complications. CPT Pharmacometrics Syst. Pharmacol. 2, e54 (2013).
25. Schaller, S. et al. A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System. CPT Pharmacometrics Syst. Pharmacol. 2, e65 (2013).
26. Hoeng, J. et al. Case study: the role of mechanistic network models in systems toxicology. Drug Discov. Today 19, 183-192 (2014).
27. Riggs, M.M., Bennetts, M., van der Graaf, P.H. & Martin, S.W. Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis. CPT Pharmacometrics Syst. Pharmacol. 1, e11 (2012).
28. Ekerot, P. et al. Systems pharmacology modeling of drug-induced modulation of thyroid hormones in dogs and translation to human. Pharm. Res. 30, 1513-1524 (2013).
29. Cucurull-Sanchez, L., Spink, K.G. & Moschos, S.A. Relevance of systems pharmacology in drug discovery. Drug Discov. Today 17, 665-670 (2012).
30. Demin, O. et al. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst. Pharmacol. 2, e74 (2013).
31. Bueters, T., Ploeger, B.A. & Visser, S.A. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov. Today 18, 853-862 (2013).
32. Soubret, A., Helmlinger, G., Dumotier, B., Bibas, R. & Georgieva, A. Modeling and simulation of preclinical cardiac safety: towards an integrative framework. Drug Metab. Pharmacokinet. 24, 76-90 (2009).
33. Kirouac, D.C. & Onsum, M.D. Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology. CPT Pharmacometrics Syst. Pharmacol. 2, e71 (2013).
34. Stone, J.A. et al. Model-based drug development survey fnds pharmacometrics impacting decision making in the pharmaceutical industry. J. Clin. Pharmacol. 50, 20S-30S (2010).
35. Jayakar, R.Y. et al. Evaluation of high-resolution peripheral quantitative computed tomography, fnite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone 50, 1379-1388 (2012).
36. Cabal, A. et al. High-resolution peripheral quantitative computed tomography and fnite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate effcacy of odanacatib and differentiation from alendronate. Bone 56, 497-505 (2013).
37. Brixen, K. et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J. Clin. Endocrinol. Metab. 98, 571-580 (2013).
38. Langdahl, B. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: fve years of continued therapy in a phase 2 study. J. Bone Miner. Res. 27, 2251-2258 (2012).
39. Kerbusch, K. et al. Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data. ACoP (2011).
40. Zandvliet, A. et al. Exposure-response modeling in suppor t of Phase 3 dose selection of MK-3222 for treatment of psoriasis. ACoP (2013).
41. Zandvliet, A. et al. Longitudinal PK-PD modeling in support of Phase 3 maintenance dose selection of MK-3222 for psoriasis. ACoP (2013).
42. Azer, K. et al. Developing ft-for-purpose physiological models in drug discovery and development-a framework for qualifcation best practices. CPT Pharmacometrics Syst Pharmacol (2014).
43. Friedrich, C., Bosley, J., Baillie, R. & Beaver, R. Qualifying mechanistic physiological models for use in pharmaceutical discovery and development. ACoP (2011).
44. Brynne, L., Bresell, A. & Sjögren, N. Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine. J. Transl. Med. 11, 250 (2013).
45. Amanfu, R.K. & Saucerman, J.J. Cardiac models in drug discovery and development: a review. Crit. Rev. Biomed. Eng. 39, 379-395 (2011).
46. Kraushaar, U. et al. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. Expert Opin. Drug Saf. 11, 285-298 (2012).
47. Roberts, B.N., Yang, P.C., Behrens, S.B., Moreno, J.D. & Clancy, C.E. Computational approaches to understand cardiac electrophysiology and arrhythmias. Am. J. Physiol. Heart Circ. Physiol. 303, H766-H783 (2012).
48. Manolis, E., Rohou, S., Hemmings, R., Salmonson, T., Karlsson, M. & Milligan, P.A. The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst. Pharmacol. 2, e31 (2013).
49. Visser, S.A., Manolis, E., Danhof, M. & Kerbusch, T. Modeling and simulation at the interface of nonclinical and early clinical drug development. CPT Pharmacometrics Syst. Pharmacol. 2, e30 (2013).
50. Ito, K. et al. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. J. Alzheimers. Dis. 37, 173-183 (2013).